About Us

Metselex is developing new first-line drugs to combat neurodegenerative diseases. 

Acute and chronic neurodegenerative diseases are the leading causes of death and disability in the world. The economic burden on society that results from treatment costs and lost productivity is substantial. Current estimates of the cost of care are almost $1T per year for chronic neurodegenerative patients just in the US, including $600B just for Alzheimer’s Disease, growing to $2T by 2050.